Galapagos NV ADR (GLPG) - Total Liabilities
Based on the latest financial reports, Galapagos NV ADR (GLPG) has total liabilities worth $119.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Galapagos NV ADR - Total Liabilities Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Galapagos NV ADR to evaluate short-term liquidity relative to the company's equity base.
Galapagos NV ADR Competitors by Total Liabilities
The table below lists competitors of Galapagos NV ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Darbond Technology Co. Ltd. A
SHG:688035
|
China | CN¥1.03 Billion |
|
Trevi Therapeutics Inc
NASDAQ:TRVI
|
USA | $7.48 Million |
|
Greatoo Inc
SHE:002031
|
China | CN¥1.92 Billion |
|
Sunway Real Estate Investment Trust
KLSE:5176
|
Malaysia | RM5.29 Billion |
|
Americas Silver Corp
TO:USA
|
Canada | CA$184.49 Million |
|
Costamare Inc
NYSE:CMRE
|
USA | $1.70 Billion |
|
DRDGOLD Limited
JSE:DRD
|
South Africa | ZAC3.36 Billion |
|
Emami Limited
NSE:EMAMILTD
|
India | Rs9.14 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Galapagos NV ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Galapagos NV ADR worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galapagos NV ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galapagos NV ADR (2004–2025)
The table below shows the annual total liabilities of Galapagos NV ADR from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.58 Million | -86.23% |
| 2024-12-31 | $1.24 Billion | -20.68% |
| 2023-12-31 | $1.56 Billion | -29.28% |
| 2022-12-31 | $2.21 Billion | -13.39% |
| 2021-12-31 | $2.55 Billion | -16.33% |
| 2020-12-31 | $3.05 Billion | -4.56% |
| 2019-12-31 | $3.19 Billion | +1317.53% |
| 2018-12-31 | $225.25 Million | -17.88% |
| 2017-12-31 | $274.29 Million | -15.51% |
| 2016-12-31 | $324.64 Million | +318.81% |
| 2015-12-31 | $77.52 Million | +20.49% |
| 2014-12-31 | $64.33 Million | -46.50% |
| 2013-12-31 | $120.24 Million | +2.87% |
| 2012-12-31 | $116.88 Million | +173.86% |
| 2011-12-31 | $42.68 Million | -6.11% |
| 2010-12-31 | $45.45 Million | +30.49% |
| 2009-12-31 | $34.83 Million | +0.96% |
| 2008-12-31 | $34.50 Million | -31.13% |
| 2007-12-31 | $50.10 Million | -13.78% |
| 2006-12-31 | $58.10 Million | +184.45% |
| 2005-12-31 | $20.43 Million | +289.38% |
| 2004-12-31 | $5.25 Million | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more